EAPB Forum: 2001/2 Editorial
NewDrugs with Pharma Biotechnology.
Biotechnology in general and Pharmaceutical Biotechnology especially belong definitely to the most promising areas of the future ? with regard to scientific but also commercial aspects. This is commonly highlighted by all market analysts and consultancy companies, venture capital is still investing large amounts of money in this part of the new market. Despite the major draw back at the stock exchange in the ?New Market? and the problems of the ?Old Market?, pharma is still performing quite well in both markets. Pharmaceutical biotechnology, nanotechnology etc. are still the key words to attract investors. This confidence is fully justified when looking at the percentage of biotech drugs being in the clinical phases I-III.
Get the whole press release as pdf-download.